All In Biotech

Free tool

FAERS Monitor: Briumvi

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761238 or its brand name (Briumvi, Ublituximab-Xiiy). Reports on generic versions are filed under their own applications.

Reports

3,894

Serious

932

24% of reports

Hospitalization

490

Death reported

67

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • infusion related reaction1,435
  • fatigue238
  • headache124
  • malaise116
  • pain109
  • urinary tract infection103
  • illness100
  • multiple sclerosis relapse99
  • asthenia94
  • gait disturbance90
  • inappropriate schedule of product administration88
  • maternal exposure during pregnancy82
  • drug ineffective80
  • multiple sclerosis80
  • off label use80

Reports by year received

View as table
YearReports
20153
20162
20172
201810
20191
202148
202226
2023247
20241,012
20251,783
2026760

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,265 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
infusion related reactionSignal1,435119.5114.6165,375
multiple sclerosisSignal809.17.3565
multiple sclerosis relapseSignal997.86.4582
illnessSignal1005.24.3341
maternal exposure during pregnancySignal825.04.0257
urinary tract infectionSignal1033.32.7161
inappropriate schedule of product administrationSignal882.62.189
gait disturbanceSignal902.52.183
fatigue2381.71.563
malaise1161.41.215
asthenia941.41.18
headache1241.10.90
pain1091.00.80
off label use800.50.443
drug ineffective800.30.3117

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.